Optical Coherence Tomography News and Research

RSS

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010.

20 Apr 2010

Handheld SD-OCT device helps examine vitreoretinal interface in infants with SBS

Ophthalmologists examining infants for possible Shaken Baby Syndrome (SBS) found that a handheld Spectral Domain Optical Coherence Tomography (SD-OCT) device provided high-resolution images of the retina and the vitreoretinal interface in infants with SBS, reports a study in the current issue of Retina, The Journal of Retinal and Vitreous Diseases.

17 Apr 2010

Optovue founds "Eye-Give" non-profit foundation

Optovue, a pioneer in fourier/spectral-domain optical coherence tomography (OCT), has founded "Eye-Give," a non-profit foundation for the purposes of donating technology and funding to sight saving charities and organizations around the world.

13 Apr 2010

OptiMedica releases new details on femtosecond laser system for cataract surgery

OptiMedica Corp., a global ophthalmic device company, has released new details regarding the development of its proprietary femtosecond laser system for cataract surgery. The new system, which combines OptiMedica's breakthrough pattern scanning technology, an ultra-fast laser and integrated Optical Coherence Tomography imaging, is designed to dramatically improve the complex cataract procedure by replacing its most technically demanding and manual steps.

12 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

MGH to create registry of patients who had OCT of coronary arteries

Massachusetts General Hospital, together with a coalition of 20 international sites in five countries, will create the world's largest registry of patients who have had optical coherence tomography of the coronary arteries.

26 Mar 2010

Stentys receives CE Marking for its self-expanding and disconnectable stent

Medical device pioneer Stentys announced today that it has received CE Marking for its self-expanding and disconnectable stent to treat acute coronary syndrome (ACS).

5 Mar 2010

Judge schedules next phase of LightLab Imaging's damages trial against Volcano and Axsun Technologies

LightLab Imaging, Inc., pioneer and leader in the development of Optical Coherence Tomography (OCT) for coronary artery applications, today reported that Trial Judge Margaret Hinkle has set March 22 for the commencement of the next phase of an ongoing trial to address damages LightLab Imaging is claiming against Volcano Corporation and its wholly owned subsidiary, Axsun Technologies, Inc.

10 Feb 2010

New screening technique identifies early signs of cancer

A new technique to catch cancer early has taken an important step forward thanks to the National Physical Laboratory (NPL). NPL's 'phantoms' will ensure an exciting new screening technique can be relied upon by hospitals to identify early signs of cancer.

27 Jan 2010

New hand-held device eliminates technical challenges involved in imaging progressive ROP in infants

Using a hand-held spectral domain optical coherence tomography (SD-OCT) imaging device, researchers have obtained high-resolution retinal scans of premature infants with progressive retinopathy of prematurity (ROP), according to a report in this month's Archives of Ophthalmology.

12 Jan 2010

ThromboGenics completes enrollment in second microplasmin Phase III trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

16 Dec 2009

ThromboGenics initiates Phase II trial of microplasmin for wet AMD

ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, announces today that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD).

11 Dec 2009

Stentys commences enrollment in its comparative stent study

Medical device pioneer Stentys announced today that the first patient has been enrolled into the ‘APPOSITION II’ clinical study—a randomized trial comparing the Stentys self-expanding stent with a conventional balloon-expandable stent in AMI patients. The primary endpoint of the ‘APPOSITION II’ study is stent strut apposition at day three post-procedure via extremely high-resolution OCT (optical coherence tomography) imaging.

4 Dec 2009

Scientists explore various imaging techniques to gain new insight into lung disease

Chronic obstructive pulmonary disease (COPD), a respiratory disease commonly known as chronic bronchitis or emphysema, is the fourth leading cause of death worldwide. 600 million people live with COPD and while researchers have yet to find any real treatment or cure, Grace Parraga of Robarts Research Institute at The University of Western Ontario in London, Canada, is using various imaging techniques to gain new insight into the disease.

21 Nov 2009

Atrium Medical presents final results of its "COCTAIL study"

Atrium Medical Corporation is proud to announce the release of the final results of the "COCTAIL Study," a clinical study comparing local administration of an anti-platelet medication with the company's proprietary infusion balloon technology.

5 Nov 2009

CWRU grants licensing agreement to Bioptigen for FDOCT technology

Case Western Reserve University and University Hospitals Case Medical Center have granted to Bioptigen, of Research Triangle Park, N.C ., an exclusive intellectual property licensing agreement for Fourier domain optical coherence tomography (FDOCT), an imaging technology developed from research at the university's Department of Biomedical Engineering.

27 Oct 2009

Latest optical and laser technology in medicine displayed at FiO meeting

From scopes that help premature babies breathe to techniques for imaging live neurons and beating hearts as they develop, the latest optical and laser technology being deployed in medicine and the biosciences will be on display at the Optical Society's (OSA) Annual Meeting, Frontiers in Optics (FiO), which takes place Oct. 11-15 at the Fairmont San Jose Hotel and the Sainte Claire Hotel in San Jose, Calif.

1 Oct 2009

Pre-clinical data demonstrates advantages of Combo Stent

OrbusNeich announced today that pre-clinical data involving porcine coronary models demonstrate that the company's Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) may offer advantages to the Cypher(R) sirolimus eluting stent and the XIENCE(TM) V everolimus eluting stent.

24 Sep 2009

ThromboGenics completes enrollment for MIVI-TRUST clinical trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the US Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

24 Sep 2009

New device for identifying eye conditions in infants

Tell-tale signs of a condition that can blind premature babies are being seen for the first time using a new handheld device in a study at Duke University Medical Center.

22 Sep 2009